市场调查报告书
商品编码
1403522
到 2030 年曲马多药品市场预测:按类型、剂型、配销通路和地区分類的全球分析Tramadol Drug Market Forecasts to 2030 - Global Analysis By Type, Dosage Form, Distribution Channel and by Geography |
根据 Stratistics MRC 的数据,2023 年全球曲马多药品市场规模为 49 亿美元,预计 2030 年将达到 88.4 亿美元,预测期内复合年增长率为 8.8%。
用于治疗疼痛的人造鸦片类止痛药称为曲马多。通常建议用于治疗中度至重度疼痛。与传统阿片类药物相比,曲马多透过与 mu-阿片类受体结合并抑制血清素和去甲肾上腺素的再摄取发挥作用。此外,与其他鸦片类药物相比,这种双重作用可以降低呼吸抑制的风险,同时也有助于药物的镇痛作用。
根据美国疾病管制与预防中心 (CDC) 的数据,美国约有 5,850 万名成年人被医生诊断出患有关节炎,预计到 2040 年将有 7,840 万人被诊断出患有关节炎。
公众和医疗保健专业人员对疼痛管理的认识日益增强,因此越来越关注安全有效的疼痛缓解方法。曲马多在疼痛治疗方面有着悠久的成功历史,并从这一发展中受益。此外,对客製化治疗方法的持续需求以及对各种疼痛管理替代方案的认识不断提高是推动製药业曲马多销售的因素。
曲马多广泛普及的障碍之一是噁心、头晕、便秘等副作用的发生。此外,重复使用可能会导致耐受性,并且需要改变剂量以保持有效性。医疗负责人必须仔细权衡镇痛的需要与控制副作用和耐受性。这项决定将影响曲马多的普遍可接受性和长期使用。
曲马多药物的持续开发存在机会。透过专注于尖端给药方法(例如联合治疗和缓释性)的研究和开发倡议,可以提高药物疗效和患者依从性。此外,解决给药频率、副作用和整体治疗结果等问题的改进配方可能会使曲马多成为更复杂、更适应性的疼痛管理解决方案。
疼痛管理市场不断变化,不断研究的结果正在开发新的治疗方法。曲马多的市场占有率面临来自非阿片类镇痛药、医疗设备和非药物干预措施的竞争的风险。此外,曲马多在功效、安全性和患者偏好方面面临着医疗保健提供者考虑的其他疼痛治疗方案的竞争。
曲马多药品市场受到了 COVID-19大流行的各种影响。由于对医疗保健和药物的日益关注,对疼痛管理解决方案的需求不断增加,但由于全球供应链的中断、医疗保健优先事项的转变以及资源重新分配到与流行病相关的动态上,市场动态正在发生变化,也受到影响。此外,医疗服务的关闭和限制也影响了患者获得护理的机会,也可能影响一般曲马多的消费量和处方实践。
在曲马多药品市场中,锭剂预计将占据最大份额。锭剂因其稳定性、便携性和易用性而受到青睐。锭剂因其保质期长、给药准确且对患者友好而受到强烈推荐。在许多治疗层级中,锭剂是一种方便且首选的型态,可以提高患者的用药医嘱遵从性。此外,由于其一致的製造流程、坚固耐用和便携的特性以及深受患者和医疗保健专业人员的欢迎,锭剂在製药行业获得了最大的市场占有率。
在曲马多药品市场中,线上药局市场成长最快。线上药局的快速扩张是由于数位平台的使用增加、电子商务的进步以及它们为客户提供的易用性。此外,人们可以在舒适的家中在线订购和获取药物,从而省去了前往实体药房的麻烦。
欧洲地区预计将占据最大份额。强大的医疗保健系统、先进的创新和强大的患者基础定义了欧洲医药市场。该地区的医药市场占有率深受德国、法国和英国等欧盟国家的影响。此外,欧洲因其大型製药公司、强大的法规环境和不断进步的医学研究而在製药界享有盛誉。
亚太地区的复合年增长率最高。由于医疗基础设施的成长、可支配收入的增加、药物研发活动的扩大以及高龄化和人口成长等因素,亚太地区的製药业正在迅速扩张。此外,中国和印度等新兴经济体专注于药品製造、创新和医疗保健,对此成长至关重要。
According to Stratistics MRC, the Global Tramadol Drug Market is accounted for $4.90 billion in 2023 and is expected to reach $8.84 billion by 2030 growing at a CAGR of 8.8% during the forecast period. An artificial opioid analgesic used to treat pain is called tramadol. It is frequently recommended for the treatment of moderate-to-severe pain. In contrast to conventional opioids, tramadol functions by inhibiting the reuptake of serotonin and norepinephrine in addition to binding to mu-opioid receptors. Moreover, when compared to other opioids, this dual action may provide a lower risk of respiratory depression while also contributing to the drug's analgesic effects.
According to Centers for Disease Control and Prevention (CDC), in the U.S. adults, about 58.5 million people had doctor-diagnosed arthritis and by 2040, an estimated 78.4 million adults will have doctor-diagnosed arthritis.
The general public and healthcare professionals are becoming more aware of pain management, and this has led to a growing focus on safe and efficient pain relief methods. With its well-established history of success in the treatment of pain, tramadol gains from this development. Additionally, the ongoing need for customized treatment regimens and growing awareness of various alternatives for managing pain are factors driving tramadol's sales in the pharmaceutical industry.
One obstacle to Tramadol's widespread use is the occurrence of side effects, which include nausea, dizziness, and constipation. Furthermore, repeated use may cause tolerance, which calls for dose changes to maintain effectiveness. Healthcare practitioners must carefully weigh the need for pain relief against the control of side effects and tolerance. This decision will affect the general acceptability and long-term use of tramadol.
There are opportunities in the ongoing development of tramadol formulations. The effectiveness of the medication and patient compliance can be improved by research and development initiatives that concentrate on cutting-edge delivery methods, such as combination therapies or extended-release formulations. Moreover, tramadol may be positioned as a more sophisticated and adaptable pain management solution with improved formulations that address problems like dose frequency, adverse effects, and overall therapeutic outcomes.
The market for pain management is always changing, and new treatments are being developed as a result of continuous research. Tramadol's market share is at risk from competition from non-opioid analgesics, medical devices, and non-pharmacological interventions. Additionally, in terms of effectiveness, safety, and patient preferences, tramadol is facing competition from other pain management options that healthcare providers are investigating.
The Tramadol medication market has experienced a variety of effects from the COVID-19 pandemic. The demand for pain management solutions has increased due to the increased focus on healthcare and pharmaceuticals; however, market dynamics have also been affected by disruptions in the global supply chain, changes in healthcare priorities, and the redirection of resources towards pandemic-related issues. Furthermore, lockdowns and limitations on healthcare services have also impacted patient access to care, which may have an impact on the general amount of tramadol consumed as well as prescribing practices.
In the tramadol drug market, the tablet segment is expected to account for the largest share. Because of their stability, portability, and simplicity of use, tablets are preferred. The extended shelf life, accurate dosage delivery, and patient-friendly qualities of these medications make them highly recommended. In many therapeutic classes, tablets provide a convenient and preferred form that is highly conducive to patient adherence to medication. Moreover, the pharmaceutical industry's largest market share is attained by tablets because of their consistent manufacturing processes, solid and portable nature, and popularity among patients and healthcare providers.
Within the Tramadol drug market, the online pharmacy segment is growing at the fastest rate. The swift expansion of online pharmacies can be attributed to the growing utilization of digital platforms, advancements in electronic commerce, and the ease of use they provide to customers. Additionally, people can order and obtain medications online from the convenience of their homes, saving them the trouble of physically visiting brick-and-mortar pharmacies.
European region is projected to hold the largest share. The robust healthcare system, elevated innovation, and substantial patient base define the European pharmaceutical market. The pharmaceutical market share of the area is largely influenced by European Union nations like Germany, France, and the United Kingdom. Moreover, Europe is well-known in the world of pharmaceuticals because of its large pharmaceutical companies, strong regulatory environments, and continuous medical research advancements.
Asia-Pacific region is growing at the highest CAGR. Due to factors like growing healthcare infrastructure, rising disposable incomes, expanding pharmaceutical research and development activities, and an aging and sizable population, the pharmaceutical industry in Asia-Pacific is expanding rapidly. Furthermore, with an emphasis on pharmaceutical manufacturing, innovation, and healthcare accessibility, emerging economies like China and India are essential to this growth.
Some of the key players in Tramadol Drug market include CSL Limited, Hexal AG, Labopharm, Amneal Pharmaceuticals, Mankind Pharma Ltd, Par Pharmaceuticals, Grunenthal Group, Nippon Shinyaku Co., Ltd., Kosher Pharmaceuticals, Mundipharma, Atoz Pharmaceuticals, Rompharm Company and Nippon Shinyaku.
In December 2023, Amneal Pharmaceuticals, Inc. and BIAL - Portela & Ca., S.A., today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® in the U.S. starting on December 18, 2023. Amneal expects to begin distribution of ONGENTYS® in early 2024.
In August 2023, Grunenthal GmbH and Kyowa Kirin Co have announced the successful completion of a deal to enter into a joint venture collaboration for Kyowa Kirin International's established medicines portfolio.The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3 for osteoporosis.
In November 2022, CSL Limited has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings to access its late stage, next-generation self-amplifying mRNA (sa-mRNA) vaccine tech: prepared to spend more than $4bn on the deal to accelerate its mRNA journey.